TH9507 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-04. Numbers and descriptions here follow the published literature rather than marketing material.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
BRINP2-related peptide (BRP) is a synthetic peptide that displays anti-obesity action similar to semaglutide. It does this without significant muscle loss or anxiety and without impacting bowel movement when administered to mice and pigs. BRP primarily stimulates receptors in the hypothalamus and is consistent with GPCR activation leading to stimulation of CREB and Fos activity in neuronal cells. Researchers at Stanford University derived BRP from the BRINP2 protein, corresponding to amino acids 386–397 (THRILRRLFNLC) of BRINP2. This 12-amino acid peptide is flanked by KK and KR recognition sites within the BRINP2 protein, which are cleaved by proprotein convertases to release the peptide. BRP has been detected in human cerebrospinal fluid by mass spectrometry. Additionally, BRP undergoes C-terminal amidation, resulting in the sequence THRILRRLFNLC-NH2. The non-amidated form of the peptide is inactive.
60 amino acids in the extracellular N-terminal domain three transmembrane helices (TM1, 2, and 3) an intracellular loop of 46 amino acids connecting TM1 and TM2 a short intracellular C-terminal domain of 15 amino acids. The homotrimeric assembly is conserved across species, from plants, yeast to mammals.
Amy Beth Schumer (born June 1, 1981) is an American stand-up comedian, actress, writer, producer, and director. Schumer ventured into comedy in the early 2000s before appearing as a contestant on the fifth season of the NBC reality competition series Last Comic Standing in 2007. From 2013 to 2016, she was the creator, co-producer, co-writer, and star of the Comedy Central sketch comedy series Inside Amy Schumer, for which she received a Peabody Award and was nominated for five Primetime Emmy Awards, winning Outstanding Variety Sketch Series in 2015. Schumer wrote and made her film debut in a starring role in Trainwreck (2015) earning a nomination for the Golden Globe Award for Best Actress – Motion Picture Comedy or Musical. She then starred in the comedy films Snatched (2017), and I Feel Pretty (2019). She created, produced and starred in the HBO documentary series Expecting Amy (2020), and the Hulu comedy-drama series Life & Beth (2022–2024). She made her Broadway debut in Steve Martin's Meteor Shower for which she earned a Tony Award nomination for Best Actress in a Play. Schumer has earned two Grammy Award nominations for Best Comedy Album for Amy Schumer: Live at the Apollo, and Best Spoken Word Album for narrating her memoir, The Girl with the Lower Back Tattoo (2016).
To facilitate the movement of marine mammals in water, the hind legs were either lost altogether, as in the whales and manatees, or united in a single tail fin as in the pinnipeds (seals). In the whale, the cervical vertebrae are typically fused, an adaptation trading flexibility for stability during swimming.
The 20 countries with the highest prevalence of obesity among adults in 2022 were mostly in the Pacific Islands, the Caribbean, and the Near East and North Africa. In Tonga (71.7 percent), Nauru (69.9 percent), Tuvalu (64.2 percent) and Samoa (62.4 percent), 60 percent or more of the adult population is obese. While the prevalence of adult obesity in the United States of America is the thirteenth-largest in the world (42.0 percent), the country is home to the largest number of obese adults due to its large population, accounting for one-eighth of the global total. The rate of obesity also increases with age at least up to 50 or 60 years old and severe obesity in the United States, Australia, and Canada is increasing faster than the overall rate of obesity. The OECD has projected an increase in obesity rates until at least 2030, especially in the United States, Mexico and England with rates reaching 47%, 39% and 35%, respectively. Once considered a problem only of high-income countries, obesity rates are rising worldwide and affecting both the developed and developing world. These increases have been felt most dramatically in urban settings. In 2021, nearly half the global adult population - a billion men and 1.11 billion women aged 25 or older - were overweight or obese. It was predicted that if these trends continue about 57.4% of men and 60.3% of women would be overweight or obese by 2050. Sex- and gender-based differences influence the prevalence of obesity. Globally there are more obese women than men, but the numbers differ depending on how obesity is measured.
Sources: en.wikipedia.org
He has published extensively on historical demography, focusing especially on long-run changes in multi-generational families, single parenthood, divorce, and marriage, and data and methods for population history. His study of the effects of demographic change on family structure won the William J. Goode Book Award from the American Sociological Association and the Allen Sharlin Memorial Award from the Social Science History Association. Ruggles's work on migration censoring in family reconstitution stimulated a debate about biases introduced by the "Ruggles Effect." Ruggles was also a prominent contributor to the debate about disclosure control in the 2020 U.S. Census. Ruggles received a 2003 Robert J. Lapham Award from the Population Association of America in recognition of lifetime contributions that blend research with the application of demographic knowledge to policy issues, and in 2009 he received the Warren E. Miller Award from the Inter-university Consortium for Political and Social Research for meritorious service to the social sciences. In 1995, Ruggles was described as the "King of Quant" by Wired Magazine, and in 2014, he was named “Wonkblog-Certified Data Wizard” by the Washington Post Wonkblog, which noted that "losing to Steven Ruggles in Name That Data is kind of like losing to Adele on American Idol." In 1994, Ruggles married Lisa Norling, another historian. They have two daughters.
=== SCOT deficiency === Succinyl-CoA:3-ketoacid CoA transferase deficiency (or SCOT deficiency) leads to a buildup of ketones. Ketones are created upon the breakdown of fats in the body and are an important energy source. Inability to utilize ketones leads to intermittent ketoacidosis, which usually first manifests during infancy. Disease sufferers experience nausea, vomiting, inability to feed, and breathing difficulties. In extreme cases, ketoacidosis can lead to coma and death. The deficiency is caused by mutation in the gene OXCT1. Treatments mostly rely on controlling the diet of the patient.
"God knows it did not cross our minds to attack the towers, but after [witnessing] [...] the destroyed towers in Lebanon, it occurred to me [to] punish the unjust the same way: to destroy towers in America, so it could taste some of what we are tasting, and to stop killing our children and women." Other motives have been suggested in addition to those stated by him and other al-Qaeda members. Some authors suggested the "humiliation" that resulted from the Islamic world falling behind the Western world—this discrepancy was rendered especially visible by globalization—as well as a desire to provoke the U.S. into a broader war against the Islamic world in the hope of motivating more allies to support al-Qaeda. Similarly, others have argued the 9/11 attacks were a strategic move to provoke America into a war that would incite a pan-Islamic revolution.
Therefore, they require multipurpose plants instead of the dedicated plants prevailing in the industry so far. At the same token, outsourcing is gaining ground. Globalization results in a shift of fine chemical production from the industrialized to developing countries. The latter benefit not only from a "low cost/high skill" advantage, but also from a rapidly rising domestic demand for Western medicine. Despite the mantras of Western industry leaders, the cost advantage of the Asian producers is going to persist. As the pharmerging countries mainly use generics, their market share continues to grow to the detriment of originator pharmaceuticals and agrochemicals. This is also the case for biosimilars, the generic versions of biopharmaceuticals. As a consequence of the harsh business climate, many Western fine chemical companies or divisions created during the "irrational exuberance" at the end of the 20th century have already exited from the sector. Others will follow suit or will be acquired by private equity firms. Survival strategies include implementing lean production principles originally developed by the automotive industry and extending the business model to also include contract research at the beginning and active drug formulation towards the end of the added value chain. This latter strategy, however, is not finding unanimous approval by industry experts.
In contrast to pregabalin, food does not significantly affect the Tmax of gabapentin and increases the Cmax of gabapentin by approximately 10%. The Tmax of the instant-release (IR) formulation of gabapentin enacarbil (as active gabapentin) is about 2.1 to 2.6 hours across all doses (350–2,800 mg) with single administration and 1.6 to 1.9 hours across all doses (350–2,100 mg) with repeated administration. Conversely, the Tmax of the extended-release (XR) formulation of gabapentin enacarbil is about 5.1 hours at a single dose of 1,200 mg in a fasted state and 8.4 hours at a single dose of 1,200 mg in a fed state. The Tmax of phenibut has not been reported, but the onset of action and peak effects have been described as occurring at 2 to 4 hours and 5 to 6 hours, respectively, after oral ingestion in recreational users taking high doses (1–3 g).
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.